Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.54 +0.62 (+3.89%)
Official Closing Price Updated: 7:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Two Board of Directors Appointments
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Participate in Citi Global Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Hold Investor Day on Nov. 13
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Third-Quarter 2025 Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Board Changes
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Participate in Upcoming Investor Conferences
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Second-Quarter 2025 Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
From Bausch + Lomb Corporation
Via Business Wire
News headline image
BAUSCH & LOMB ALERT: Bragar Eagel & Squire, P.C. is Investigating Bausch + Lomb Corporation on Behalf of Bausch & Lomb Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.